EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 191 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $12,000 | -40.0% | 0 | -100.0% | 0.00% | – |
Q2 2022 | $20,000 | -9.1% | 453 | 0.0% | 0.00% | – |
Q1 2022 | $22,000 | -4.3% | 453 | 0.0% | 0.00% | – |
Q4 2021 | $23,000 | -8.0% | 453 | 0.0% | 0.00% | – |
Q3 2021 | $25,000 | +31.6% | 453 | 0.0% | 0.00% | – |
Q2 2021 | $19,000 | 0.0% | 453 | 0.0% | 0.00% | – |
Q1 2021 | $19,000 | -38.7% | 453 | -32.2% | 0.00% | – |
Q4 2020 | $31,000 | +10.7% | 668 | 0.0% | 0.00% | – |
Q3 2020 | $28,000 | -12.5% | 668 | 0.0% | 0.00% | – |
Q2 2020 | $32,000 | -74.2% | 668 | -75.3% | 0.00% | – |
Q1 2020 | $124,000 | -23.5% | 2,700 | 0.0% | 0.00% | – |
Q4 2019 | $162,000 | +5.9% | 2,700 | 0.0% | 0.00% | – |
Q3 2019 | $153,000 | -81.7% | 2,700 | -82.0% | 0.00% | – |
Q2 2019 | $834,000 | +20750.0% | 15,000 | +14900.0% | 0.00% | – |
Q4 2018 | $4,000 | -81.0% | 100 | -66.7% | 0.00% | – |
Q3 2018 | $21,000 | -81.4% | 300 | -80.0% | 0.00% | – |
Q2 2018 | $113,000 | +606.2% | 1,500 | +400.0% | 0.00% | – |
Q1 2018 | $16,000 | -91.2% | 300 | -91.2% | 0.00% | – |
Q4 2017 | $182,000 | -42.4% | 3,400 | -35.8% | 0.00% | -100.0% |
Q3 2017 | $316,000 | – | 5,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |